Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: R. A. Freedman, H. Heiling, K. J. Ruddy, L. Rogak, M. Sedrak, A. Dueck, H. Liu, A. Fraettarelli, S. Atanasov, M. DeMeo, P. Lange, A. Perilla Glen, S. Sinclair, D. Dillon, J. Mortimer, M. Fenton, J. Walsh, L. Spring, H. Muss, N. Sinclair, E. Hamilton, C. Dang, S. Giordano, M. Faggen, S. Lo, C. Kuzma, S. Lemke, P. Stella, R. Mowat, M. Wilkinson, J. Rauch, N. Tayob, E. Winer
Institutions: Dana-Farber Cancer Institute, Mayo Clinic, Mayo Clinic in Arizona, University of California, Los Angeles, Brigham and Women's Hospital, City Of Hope National Medical Center, City of Hope, Brown University, Mass General Brigham, UNC Lineberger Comprehensive Cancer Center, Dana-Farber Brigham Cancer Center, Sarah Cannon, Memorial Sloan Kettering Cancer Center, Boston Medical Center, South Shore Hospital, Stamford Hospital, FirstHealth of the Carolinas, Upstate University Hospital, Toledo Clinic Cancer Center, Toledo Clinic Cancer Center, Johns Hopkins University, Sibley Memorial Hospital, Yale University, Smilow Cancer Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129538384